Innovative Immunological and Target Therapies for NMIBC: Recent Clinical Trial Data Shaping the Future : Episode 5
Opinion
Video
BOND-003 Trial and Cretostimogene for Treatment of NMIBC
Author(s):
Panelists discuss how cretostimogene grenadenorepvec is an intravesical oncolytic virus therapy targeting BCG-unresponsive bladder cancer through selective replication in tumor cells and immune stimulation via granulocyte-macrophage colony-stimulating factor expression.
Video Player is loading.
Video content above is prompted by the following:
- What is cretostimogene grenadenorepvec? Please describe its mechanism of action.
- Discuss the phase 3 BOND-003 clinical trial investigating the use of the intravesical immunotherapy cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive disease that was recently presented at the Society of Urologic Oncology 2024.
- What are your impressions of the BOND-003 data?
Related Videos
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
BPH Management: Patient Outcome Evolution
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Final Thoughts and Clinical Trials in NMIBC
Uptake of New Treatments in Urology Practice
Patient Communication and Treatment Adherence in NMIBC
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Resective Surgery and Minimally Invasive Procedures For BPH
Related Content
